Notice of annual general meeting in Alligator Bioscience AB
The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 (“Alligator”), are invited to the annual general meeting to be held on Tue ...
The Nomination Committee’s proposal regarding the board of directors ahead of the annual general meeting 2021 in Alligator Bioscience AB
Ahead of the annual general meeting in Alligator Bioscience AB on June 1, 2021, the Nomination Committee announces its proposals regarding C ...
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
Lund, Sweden, April 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research coll ...
Alligator Bioscience postpones the Annual General Meeting to June 1, 2021
Lund, Sweden, April 3, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the board of directors has decided to post ...
Alligator Bioscience appoints Søren Bregenholt as new CEO
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søre ...
Alligator Bioscience publishes Annual Report for 2020
Lund, Sweden, March 18, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2020 has been publi ...
Mitazalimab synergizes with chemotherapy – Alligator Bioscience presents new preclinical data at AACR
Lund, Sweden, March 11, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that an abstract for a poster presentation at ...
Change in number of shares and votes in Alligator Bioscience AB
During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of ...
Alligator Bioscience AB: Year-end Report January-December 2020
Continued focus on clinical development. “Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with meta ...